CLPT trades 10.0% above Wall Street's consensus target of $16.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CLPT achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 3 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 23, 2026, ClearPoint Neuro, Inc. (CLPT) has a Wall Street consensus price target of $16.00, based on estimates from 3 covering analysts. With the stock currently trading at $17.06, this represents a potential downside of -10.0%. The company has a market capitalization of $512M.
Analyst price targets range from a low of $16.00 to a high of $16.00, representing a 0% spread in expectations. The median target of $16.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CLPT trades at a trailing P/E of -19.0x. Analysts expect EPS to grow -13.2% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
NVCRNovoCure Limited | $1.5B | $13.61 | $33.00 | +131.1% | Buy | — | 15 |
INVAInnoviva, Inc. | $1.7B | $22.67 | $37.00 | +64.5% | Buy | 6.3x | 10 |
ABTAbbott Laboratories | $152.6B | $87.78 | $127.46 | +44.2% | Buy | 16.1x | 41 |
MDTMedtronic plc | $101.8B | $79.27 | $95.80 | +20.7% | Buy | 13.3x | 51 |
ANGOAngioDynamics, Inc. | $515M | $12.39 | $16.50 | +35.8% | Hold | — | 11 |
ATECAlphatec Holdings, Inc. | $1.3B | $8.55 | $18.00 | +104.3% | Buy | 27.5x | 18 |
GEGE Aerospace | $371.0B | $355.12 | $380.14 | +6.3% | Buy | 47.4x | 34 |
GEHCGE HealthCare Technologies Inc. | $27.6B | $60.64 | $81.10 | +31.7% | Buy | 12.6x | 18 |
SYKStryker Corporation | $116.7B | $304.64 | $387.46 | +25.9% | Buy | 20.5x | 51 |
ISRGIntuitive Surgical, Inc. | $143.1B | $402.95 | $597.78 | +47.0% | Buy | 38.9x | 55 |
Quick answers to the most common questions about buying CLPT stock.
Wall Street's consensus price target for CLPT is $16, -10.0% from its current price of $17.06. The below-market target from 3 analysts suggests limited near-term appreciation.
CLPT has a consensus rating of "Buy" based on 3 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $16 implies -10.0% downside from current levels.
CLPT's current price is $17.06 with a consensus target of $16 (-10.0% implied move). Analyst estimates suggest the stock is overvalued at current levels.
The most bullish Wall Street analyst has a price target of $16 for CLPT, while the most conservative target is $16. The consensus of $16 represents the median expectation. These targets typically reflect 12-month expectations.
CLPT is lightly followed, with 3 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CLPT stock forecast based on 3 Wall Street analysts shows a consensus price target of $16, with estimates ranging from $16 (bear case) to $16 (bull case). The median consensus rating is "Buy".
Analysts are cautious on CLPT, with 0 Sell ratings and a price target of $16 (-10.0% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CLPT analyst price targets range from $16 to $16, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $16 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.